Intrinsic Therapeutics

MA - WoburnMedical Devices5 H-1B visas (FY2023)

Focus: Intrinsic Therapeutics is a publicly traded medical device company headquartered in Woburn, MA, specializing in lumbar discectomy implants and related spinal interventions. The company focuses on preventing reherniation after back surgery through devices like Barricaid.

Hematology Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Intrinsic Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Intrinsic Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

3/9 — Basic

Company HealthSolid

Pipeline

Early-stage

11 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

Barricaid

Lumbar Disc Herniation

Growth

Lead Phase 4 product with next-generation narrow anchor variant announced March 2026, designed to reduce reherniation rates post-discectomy.

Intrinsic Hepcidin IDx™ Test

Anemia, Iron Deficiency

Help build intelligence for Intrinsic Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company with established market presence in spinal surgery, offering stability and potential equity upside
Perfect 5-0 H1B approval track record (2023) signals strong visa sponsorship capability for international talent
Focused pipeline in high-unmet-need area (lumbar disc herniation) with Phase 4 programs indicating commercialization-stage progress

Watch Out For

Zero active job openings as of data snapshot indicates minimal hiring momentum or potential organizational constraint
Diversified but shallow pipeline (10 trials across disconnected indications including hematology, respiratory, and PE) suggests lack of focused development strategy
Limited public financial data and patent cliff information creates uncertainty around long-term trajectory and restructuring risk

Generated by Claude from Intrinsic Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Diagnostic test with single trial in pipeline, indicating diversification into hematology diagnostics beyond core spinal franchise.

The Angel® Catheter

Pulmonary Embolism

Growth

Single-trial program in respiratory/vascular space, suggesting exploratory expansion beyond core spinal competency.

Pipeline & Clinical Trials

TMS combined with EEG

Sleep

N/A

Clinical Trials (1)

NCT07523191Validation of Presence-IP1.0 for Detection of Consciousness Using Reduced-Montage TMS-EEG

N/A

Follow up per standard of care

Lumbar Disc Herniation

N/A

Clinical Trials (1)

NCT03180749Post-Marketing Clinical Follow-Up of a Spine Implant

N/A

Annular closure

Lumbar Disc Herniation

N/A

Clinical Trials (1)

NCT05467072PMCFU of an Annular Closure System

N/A

Barricaid

Lumbar Disc Herniation

N/A

Clinical Trials (1)

NCT01534065Barricaid EU Post Market Study for Primary Lumbar Disc Herniation

N/A

Incidence of Large Annular Defects in Primary Lumbar Discectomy Patients

Lumbar Disc Herniation

N/A

Clinical Trials (1)

NCT03252691Incidence of Large Annular Defects in Primary Lumbar Discectomy Patients

N/A

Annular closure device

Lumbar Disc Herniation

N/A

Clinical Trials (1)

NCT03986580Study of Lumbar Discectomy With Annular Closure

N/A

The Angel® Catheter

Pulmonary Embolism

N/A

Clinical Trials (1)

NCT02186223The Angel® Catheter Pivotal Clinical Trial

N/A

Discectomy

Lumbar Spine Disc Herniation

N/A

Clinical Trials (1)

NCT02477176Lumbar Discectomy Control Study, Risk Factors for Reherniation

N/A

Intrinsic Hepcidin IDx™ Test

Anemia, Iron Deficiency

N/A

Clinical Trials (1)

NCT03310736Serum Hepcidin Immunoassay - Laboratory to Marketplace

N/A

Barricaid

Lumbar Disc Herniation

PHASE_4

Clinical Trials (1)

NCT01283438A Prospective, Randomized, Multicenter Study to Demonstrate the Superiority of the Barricaid to Discectomy for Primary Lumbar Disc Herniation

Phase 4

6mm annular closure device

Lumbar Disc Herniation

PHASE_4

Clinical Trials (1)

NCT03366779A Post Marketing Surveillance Study

Phase 4